
Molecure S.A.
Research and experimental development in natural sciences and engineering
Overview
Molecure is a biotechnology company that discovers and develops first-in-class small-molecule drugs for diseases with significant unmet clinical need. It focuses on unique and unexplored protein targets and has a broad pipeline of drug candidates, including therapies for inflammatory and fibrotic diseases.
Financials
Revenue history (in m)
Filing timeliness
Financial statements were filed on time, on average 25 days early. All were audited by a statutory auditor.
- 202503/07/2026
- 202408/07/2025
- 202318/06/2024
- 202205/07/2023
- 202115/07/2022
- 202014/07/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Stock quotes
- Open
- PLN 5.46
- High
- PLN 5.55
- Low
- PLN 5.33
- Volume
- 27.95K
- Avg. vol.
- 37.04K
- Market cap
- PLN 135.24M
- P/E ratio
- –
- EPS
- -PLN 0.45
- Shares outstanding
- 24.72M
- 52-week
- PLN 5.16 – 5.70
- Dividend yield
- –
- Dividend
- –
- Ex dividend date
- –
- ISIN
- PLONCTH00011
- Exchange
- GPW Main Market
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q3 2026 | USD 178.55k | USD -791.19k | USD -779.58k |
| Q2 2026 | USD 378.71k | USD -609.67k | USD -607.78k |
| Q1 2026 | USD 32.14k | USD -1.10m | USD -1.10m |
| Q4 2025 | USD 642.39k | USD -492.72k | USD -473.13k |
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
News
Molecure Receives Positive IDMC Recommendation to Continue the KITE Clinical Trial Without Changes to the Study Protocol (OATD-01 Development Program)
The Independent Data Monitoring Committee (IDMC) recommended continuation of the global Phase II PoC study in patients with active pulmonary sarcoidosis without any changes to the current study protocol. The positive recommendation was issued following the IDMC’s review of the complete safety and efficacy dataset specified for the interim analysis in 30 patients and confirms
Molecure focuses on the most commercially promising projects and closes the RNA program
Molecure is focusing its financial and operational resources on the most promising clinical programs: OATD-01 and OATD-02, as well as on the development of a service using a drug discovery and development tool, co-financed under the FENG program The Company has decided to discontinue the development of the RNA platform and to suspend all research
Invitation to investor meeting 2nd April 2025, 1:00 pm (CET)
Molecure S.A. is pleased to invite you to a meeting dedicated to the presentation of the progress of the ongoing research programmes, in particular clinical trials, as well as the development plans for the next quarters and the discussion of the Company's operational and financial situation for 2024. The meeting will be attended by: –
Molecure (WSE: MOC) and Nasdaq-listed Ocean Biomedical (NASDAQ: OCEA) sign exclusive licensing agreement for development and commercialization of selective YKL-40 inhibitors
This license covers first-in-class small molecule YKL-40 inhibitors, including the lead molecule OAT-3912, which has shown potential therapeutic benefits in preclinical models in various cancers as well as inflammatory and fibrotic diseases, offering a novel approach to treating these conditions. In addition, the license covers a patent pending for a molecular screening test for further
Molecure on the threshold of a breakthrough in treating inflammatory and fibrotic diseases – focus on the most promising therapy and OATD-01 and OATD-02 clinical trial results
Molecure has reduced the number of active projects from seven to five, focusing resources on the most promising assets; Key areas for further development and value building for Molecure are: OATD-01 as a potential breakthrough therapy for the treatment of sarcoidosis and MASH, and OATD-02 in trials in patients with solid tumors. Development of projects
Invitation to investor meeting on 16 October 2024, 10:00 am (CET)
Molecure S.A. is pleased to invite you to a meeting to discuss the Company's operational and financial situation following the publication of its Q3 2024 report, in particular the progress of ongoing clinical and preclinical stage research programs and further plans. The expected time of the meeting is about 90 minutes. The meeting will be
Industry
Offer
- Drug development
- Small-molecule drug candidates
- Preclinical testing
- Clinical trials
Websites
The site is available in: Polish and English.
- molecure.comMolecureWordPress 7.1Google AnalyticsGoogle Tag ManagerWWPMLApache
Job offers
The company has its own careers page: molecure.com/careers.
Authorized Representatives
Manner of representation
In the case of a one-person management board, the President of the Management Board is authorised to perform legal acts and make declarations on behalf of the company independently. In the case of a multi-member management board, any two members of the management board acting jointly or any member of the management board jointly with a commercial proxy are authorised to perform legal acts and make declarations on behalf of the company.
Supervisory board
Beneficial owners
Molecure is a public company listed on the Warsaw Stock Exchange, so it does not report beneficial owners to the CRBR (Art. 58 of the Polish AML Act). Its shareholders are disclosed in stock-exchange reports.
Bank accounts
Registered as a VAT taxpayer on 2012-04-13.
29 1090 1883 0000 0001 3183 5657
23 1090 1883 0000 0001 3653 9489
89 1090 1883 0000 0001 3129 3220
Debt
No entries in the National Debtors Register (KRZ).
MSiG notices
| Publication date | Event | |
|---|---|---|
| May 17, 2018 | Commercial Companies Code notice | |
| Sep 25, 2017 | Bankruptcy notice |
Public aid
20 public aid cases recorded, with a total value of $40,369,134.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Mar 30, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $18,750$18,750 | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości | |
| Dec 9, 2025 | Aid for research and development projects: industrial research | $6M$5,983,773 | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Dec 9, 2025 | Aid for research and development projects: experimental development | $804.6K$804,574 | Dyrektor Narodowego Centrum Badań i Rozwoju |
European Funds
4 projects recorded: 3 from FE lists ($16,303,134) and 1 Commission grant (FTS) ($705,306).
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2025-10-01 | Development of a new service for discovering small-molecule compounds with therapeutic potential using artificial intelligence models | $9M$8,972,255 | European Funds for a Modern Economy | |
| 2025-08-01 | Preparation of an application for a Eurogrant planned under the EIC Accelerator Open 2025 programme | $17,431$17,431 | European Funds for a Modern Economy | |
| 2023-05-10 | A breakthrough service for discovering new small-molecule drugs targeting mRNA for incurable diseases | $7.3M$7,313,447 | European Funds for a Modern Economy |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| JJP Biologics sp. z o.o. | $4,998,735.31 | jjpbiologics.com | ||
| Captor Therapeutics S.A. | $2,286,539.43 | captortherapeutics.pl | ||
| Neuca Clinical Trials Investments sp. z o.o. | $1,803,742.35 | neuca.pl | ||
| Aslab Science P.S.A. | $1,504,132.17 | aslabsci.com | ||
| Pikralida sp. z o.o. | $1,151,165.63 | pikralida.eu | ||
| Nanogroup S.A. | $843,099.47 | nanogroup.eu | ||
| Bioresearch Group sp. z o.o. | $776,186.19 | bioresearch.pl | ||
| Precisionlife Poland sp. z o.o. | $617,020.34 | precisionlife.com | ||
| Vasa Therapeutics sp. z o.o. | $363,111.30 | vasatherapeutics.com | ||
| Medicofarma Biotech S.A. | $314,882.33 | medicofarmabiotech.pl |
Change history
| Date | Event | |
|---|---|---|
| 2026-05-20 | Share capital increase (206,031.55 PLN → 247,237.86 PLN) | |
| 2025-09-01 | PKD change (Removed: 4 codes; Added: 3 codes) | |
| 2025-05-14 | Share capital increase (202,032.00 PLN → 206,031.55 PLN) | |
| 2024-12-24 | Share capital increase (168,360.00 PLN → 202,032.00 PLN) | |
| 2023-08-16 | Share capital increase (140,600.00 PLN → 168,360.00 PLN) |
FAQ
Last updated: 2026-10-18